Novo Nordisk A/S
Stocks making the biggest moves midday: Edison International, eBay, Getty Images and more
Check out the companies making headlines in midday trading. eBay – Shares jumped 9.7% and touched 52-week highs after announcing that Meta is testing using its listings on Facebook Marketplace . Buyers from Facebook will be redirected to eBay to complete transactions. The gain put the stock on track for its best day since late […]
Read More
Stocks making the biggest moves premarket: SolarEdge, Novo Nordisk, Rigetti, Maplebear and more
Check out the companies making headlines before the bell. SolarEdge Technologies — The solar stock dropped 6%. Citi downgraded SolarEdge to sell from neutral, saying the company faces “stubbornly high” operating expenses despite its restructuring announcement. Shares moved 6.6% and 8% higher on Monday and Tuesday, respectively, after SolarEdge said in a filing Monday it […]
Read More
Want to invest in weight loss drugs? Here’s where UBS thinks they’re headed in 2025
The biopharma sector has been hotly watched among investors over the past two years amid a boost to the industry by the growing popularity of the glucagon-like peptide-1 (GLP-1) drugs used in weight loss treatments. Looking ahead into 2025, however, UBS foresees that the sector “will find it difficult to outperform against a more uncertain […]
Read More
Digital health companies got pummeled by Wall Street in 2024 as industry adapts to post-Covid slowdown
Doximity at the New York Stock Exchange for their IPO, June 24, 2021. Source: NYSE If the Covid era marked a boom time for digital health companies, 2024 was the reckoning. In a year that saw the Nasdaq jump 32%, surpassing 20,000 for the first time this month, health tech providers largely suffered. Of 39 […]
Read More
FDA says the Zepbound shortage is over. Here’s what that means for compounding pharmacies, patients who used off-brand versions
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters The roughly $1,000 monthly price tag of Eli Lilly‘s weight loss drug Zepbound put the blockbuster treatment out of reach for Willow Baillies, 29, whose insurance does not cover it. Baillies, […]
Read More
European markets open higher in shortened session ahead of Christmas
European markets opened higher on Tuesday, in a shortened trading session for Christmas Eve. Stocks in Europe ended Monday’s session slightly higher, as investors reacted to more disappointing economic news out of the U.K., and the pan-European Stoxx 600 was lifted by a recovery in the share price of pharmaceuticals giant Novo Nordisk. There is […]
Read More
The ‘weight-loss trade’ has stalled. What it will take to revive investor interest
Anyone who’s been on a diet can likely relate: Those first lost pounds are met with a sense of euphoria. The voice inside one’s head screams: “I’ve got this!” But then, it inevitably becomes a slog. The initial novelty wears off, and the real work begins. Investors may see a parallel to the initial elation […]
Read More
Eli Lilly looks to extend its winning streak over the broader market to 6 years
Eli Lilly has outperformed the S & P 500 for five straight years as Wall Street woke up to its massive opportunity in obesity drugs. Six in a row is not out of the question. Year-to-date performance: Up 33.7% Forward price-to-earnings ratio: 34.3 versus five-year average of 34.5 Our rating: Buy-equivalent 1 Our price target: […]
Read More
Stocks making the biggest moves midday: Nordstrom, Honda, MicroStrategy, Broadcom and more
Check out the companies making headlines in midday trading: Nordstrom — The department store shares dipped more than 1% after announcing it will become a private company. Nordstrom agreed to a buyout deal valued at roughly $6.25 billion from its founding family and Mexican department store El Puerto de Liverpool. Common shareholders will receive $24.25 […]
Read More
Stocks making the biggest moves premarket: Novo Nordisk, Honda, Xerox, Tesla and more
Check out the companies making headlines in premarket trading. Novo Nordisk — The stock jumped about 5%, rebounding from the nearly 18% losses seen in the previous session. On Friday, the Danish pharmaceutical giant’s experimental weight loss drug, CagriSema, reported late-stage trial results that missed expectations . Honda – U.S.-listed shares surged 15% after the […]
Read More